InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.45
(
-1.86%
)
US TECH 100
19,460.00
(
0.55%
)
Dow Jones
41,763.46
(
-0.90%
)
Brent Oil
74.03
(
0.02%
)
Bitcoin
70,050.38
(
-0.22%
)
Post# of 253503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120650
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RNsidersbuying post# 234632

Sunday, 11/15/2020 5:29:13 PM

Sunday, November 15, 2020 5:29:13 PM

Post# of 253503
ABUS_reports_additional_phase-1_data_for_AB-729_in_HBV:

https://www.globenewswire.com/news-release/2020/11/15/2126904/0/en/Arbutus-Announces-Presentation-of-Phase-1a-1b-Clinical-Trial-Results-for-AB-729-in-Chronic-Hepatitis-B-Subjects-at-The-Liver-Meeting-Digital-Experience-The-American-Association-for.html

The new data are HBsAg measurements at 12w (n=7), 16w (n=7), and 20w (n=3) for the 60mg/q4w cohort.

AB-729 is an injected RNAi agent that targets multiple HBV antigens.

ABUS and ASMB are jointly running a phase-2 trial of ABUS’ AB-729 and ASMB’s ABI-H0731 (#msg-157913492), despite the fact that ABI-H0731 is effectively obsolete (#msg-159327881).

Please see #msg-155730326, #msg-155712858, #msg-154597458, and #msg-152274693 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up